Tango Therapeutics (NASDAQ:TNGX) Shares Down 3.1%

Tango Therapeutics Inc (NASDAQ:TNGX) shares traded down 3.1% on Thursday . The stock traded as low as $8.35 and last traded at $8.41. 1,251 shares traded hands during trading, a decline of 99% from the average session volume of 137,788 shares. The stock had previously closed at $8.68.

TNGX has been the subject of several recent analyst reports. SVB Leerink initiated coverage on Tango Therapeutics in a report on Monday, September 20th. They issued an “outperform” rating for the company. Zacks Investment Research raised Tango Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 23rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $16.50.

The business’s fifty day simple moving average is $10.89.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Tuesday, November 9th. The company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.02). The company had revenue of $6.79 million during the quarter, compared to the consensus estimate of $6.11 million. Analysts anticipate that Tango Therapeutics Inc will post -1.27 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Citigroup Inc. acquired a new position in Tango Therapeutics in the third quarter valued at approximately $41,000. Penserra Capital Management LLC bought a new stake in shares of Tango Therapeutics during the third quarter valued at approximately $133,000. Victory Capital Management Inc. bought a new stake in Tango Therapeutics during the third quarter worth $143,000. Cubist Systematic Strategies LLC bought a new stake in Tango Therapeutics during the third quarter worth $204,000. Finally, Bank of New York Mellon Corp bought a new position in Tango Therapeutics in the 3rd quarter valued at $326,000. 88.40% of the stock is currently owned by hedge funds and other institutional investors.

About Tango Therapeutics (NASDAQ:TNGX)

Tango Therapeutics Inc is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc, formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

Read More: Does a trade war provide a risk to the global economy?

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.